CHA News

FDA Authorizes Pediatric COVID-19 Vaccines, CDC Advisers Meet this Week 

For CEOs, CMOs, CNOs, COOs, and infection prevention, quality & patient safety, employee safety staff

This post has been archived and contains information that may be out of date.

The U.S. Food and Drug Administration (FDA) has authorized the emergency use of the Pfizer-BioNTech COVID-19 vaccine for children ages 5 through 11.  

The Pfizer-BioNTech COVID-19 vaccine for children in this age group is administered as a two-dose primary series, three weeks apart, but is a lower dose (10 micrograms) than that used for ages 12 older (30 micrograms).  

The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices will meet on Nov. 2 to provide recommendations on the pediatric COVID-19 vaccine, prior to formal authorization by the CDC director.